CandlesenseCandlesense
News/Companies/LGVN

LGVN News

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

LGVN

MIAMI, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the quarter ended June 30, 2025 and provided a business update.

August 13, 2025Earnings
Read more →

Longeveron Q1 EPS $(0.34) Misses $(0.30) Estimate, Sales $381.00K Miss $608.25K Estimate

LGVN

May 8, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Longeveron, Maintains $10 Price Target

LGVN

March 21, 2025
Read more →

Longeveron Says Co. And FDA Reached Foundational Alignment On Overall Study Design Supporting Laromestrocel In Alzheimer's Disease

LGVN

March 20, 2025
Read more →

Longeveron Publishes Results Of Phase 2a Clinical Trial Evaluating Laromestrocel In Alzheimer's Disease In Nature Medicine

LGVN

March 11, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Longeveron, Maintains $10 Price Target

LGVN

March 3, 2025
Read more →

Longeveron FY 2024 GAAP EPS $(2.62) Beats $(3.53) Estimate, Sales $2.392M Beat $2.143M Estimate

LGVN

February 28, 2025
Read more →

Longeveron Announces WHO Approval Of Non-Proprietary Name Laromestrocel For Cellular Therapy Lomecel-B In Alzheimer's And HLHS Treatment

LGVN

February 18, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on Longeveron, Maintains $10 Price Target

LGVN

November 4, 2024
Read more →

HC Wainwright & Co. Reiterates Buy on Longeveron, Maintains $12 Price Target

LGVN

May 17, 2024
Read more →

Longeveron's Return On Capital Employed Insights

LGVN

Longeveron (NASDAQ:LGVN) brought in sales totaling $466 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 60.23%, resulting in a loss of $5.62 million.

September 9, 2022
Read more →